Biomarker & Intervention Discovery

Overactive Bladder (OAB)

This page lists 8 druggable gene targets, 39 approved or trial-tested drug candidates and 15 recent clinical trials for Overactive Bladder (OAB), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Spontaneous remissionSpontaneous fluctuation common; resolution in ~25% at 1 year; bladder training alone achieves 50-80% improvement in…
Best-intervention remissionBladder training + pelvic floor exercises: 60-80% improvement (first-line guideline recommendation)…
Gap sizeLarge — most patients receive pharmacotherapy as first-line without adequate behavioural therapy trial…
Primary barrierframing/practice
Full remission profile →

Remission & chronicity

Spontaneous remission
Spontaneous fluctuation common; resolution in ~25% at 1 year; bladder training alone achieves 50-80% improvement in urgency frequency; OAB worsens with age without intervention
Best-intervention remission
Bladder training + pelvic floor exercises: 60-80% improvement (first-line guideline recommendation); anticholinergics/beta-3 agonist (mirabegron): 30-60% significant improvement; botulinum toxin A (OnabotulinumtoxinA, Botox): 30-50% complete continence at 12 weeks; sacral neuromodulation (InterStim): 72% success at 5 years
Gap size
Large — most patients receive pharmacotherapy as first-line without adequate behavioural therapy trial; anticholinergics overused in elderly
Primary barrier
framing/practice
Behavioural interventions (pelvic floor training, bladder diary, timed voiding) are first-line by all guidelines but most patients receive anticholinergics immediately; anticholinergic cognitive burden in elderly patients is significant (dementia risk association with chronic use — JAMA Intern Med 2019); mirabegron has better cognitive safety profile but is underused relative to older anticholinergics

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ADRB2 368ADRB3 255CHRM2 317CHRM3 333P2RX3 202SNAP25 11TRPA1 186TRPV1 187
Therapeutic Agent Effect Direction Evidence Tier Potency Source
METAPROTERENOL ↑ activates Mechanistic
PROPRANOLOL HYDROCHLORIDE ↓ inhibits Mechanistic
OLODATEROL ↑ activates Mechanistic
TIMOLOL ↓ inhibits Mechanistic
CHEMBL:CHEMBL1465049 ? unclear Mechanistic
NOREPINEPHRINE ↑ activates Mechanistic
EPHEDRINE SULFATE ↑ activates Mechanistic
LEVALBUTEROL ? unclear Mechanistic
3-O-METHYLQUERCETIN ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
CLENBUTEROL ↑ activates Mechanistic
ARFORMOTEROL ? unclear Mechanistic
CELIPROLOL ↑ activates Mechanistic
ISOPROTERENOL ↑ activates Mechanistic 0.1585 nM (EC50)
MEPHENTERMINE SULFATE ↑ activates Mechanistic
CARVEDILOL ↓ inhibits Mechanistic
PROCATEROL ↑ activates Mechanistic
CHEMBL:CHEMBL590927 ? unclear Mechanistic
TERTATOLOL ? unclear Mechanistic
FENOTEROL ↑ activates Mechanistic
MEPINDOLOL ? unclear Mechanistic
PROPAFENONE ↓ inhibits Mechanistic
CHEMBL:CHEMBL531322 ? unclear Mechanistic
CARMOTEROL ↑ activates Mechanistic
PINDOLOL ↓ inhibits Mechanistic
SALMETEROL ↑ activates Mechanistic
CGP12177 ↓ inhibits Mechanistic
CLENBUTEROL HYDROCHLORIDE ? unclear Mechanistic
NADOLOL ↓ inhibits Mechanistic
DESIPRAMINE ? unclear Mechanistic
CIMATEROL ↑ activates Mechanistic
FENOTEROL HBR ? unclear Mechanistic
RITODRINE ? unclear Mechanistic
PF-00610355 ? unclear Mechanistic
SOTALOL ↓ inhibits Mechanistic
TERBUTALINE ↑ activates Mechanistic
LAS190792 ↑ activates Mechanistic
NORADRENALINE ↑ activates Mechanistic
LEVOBUNOLOL HYDROCHLORIDE ↓ inhibits Mechanistic
PENBUTOLOL SULFATE ↓ inhibits Mechanistic

Showing top 40 of 368 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
FENOTEROL ↑ activates Mechanistic
MIRABEGRON ↑ activates Mechanistic
RAFABEGRON ↑ activates Mechanistic 0.062 nM (EC50)
CGP12177 ↑ activates Mechanistic
NIPRADILOL ? unclear Mechanistic
TRIHEXYPHENIDYL ? unclear Mechanistic
ISOPROTERENOL ↑ activates Mechanistic 1000.0 nM (EC50)
BOPINDOLOL ? unclear Mechanistic
AMOSULALOL ? unclear Mechanistic
CARVEDILOL ↓ inhibits Mechanistic
NOREPINEPHRINE BITARTRATE ↑ activates Mechanistic
EPHEDRINE HYDROCHLORIDE ↑ activates Mechanistic
L742791 ↑ activates Mechanistic
EPINEPHRINE BITARTRATE ↑ activates Mechanistic
LY-377604 ? unclear Mechanistic
TALIBEGRON HYDROCHLORIDE ? unclear Mechanistic
PINDOLOL ↓ inhibits Mechanistic
VIBEGRON ↑ activates Mechanistic
MN-246 ? unclear Mechanistic
EPHEDRINE SULFATE ↑ activates Mechanistic
EPINEPHRINE ↑ activates Mechanistic
L 755507 ↑ activates Mechanistic
DILEVALOL HYDROCHLORIDE ↓ inhibits Mechanistic
CARVEDILOL PHOSPHATE ↓ inhibits Mechanistic
RIMITEROL ? unclear Mechanistic
BITOLTEROL ? unclear Mechanistic
CARAZOLOL ↑ activates Mechanistic
DROXIDOPA ↑ activates Mechanistic
LY377604 ↑ activates Mechanistic
SOLABEGRON ↑ activates Mechanistic
NOREPINEPHRINE ↑ activates Mechanistic
AMIBEGRON ↑ activates Mechanistic
L-748337 ↓ inhibits Mechanistic
LABETALOL HYDROCHLORIDE ↓ inhibits Mechanistic
CL316243 ↑ activates Mechanistic
ISOPROTERENOL SULFATE ↑ activates Mechanistic
ISOPROTERENOL HYDROCHLORIDE ↑ activates Mechanistic
ABEDITEROL ↑ activates Mechanistic
ICI118551 ↓ inhibits Mechanistic
[3H]L748337 ↓ inhibits Mechanistic

Showing top 40 of 255 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TIOTROPIUM ↓ inhibits Mechanistic
[3H]OXOTREMORINE-M ↑ activates Mechanistic
SOFPIRONIUM BROMIDE ↓ inhibits Mechanistic
ASM-024 ↓ inhibits Mechanistic
FESOTERODINE FUMARATE ↓ inhibits Mechanistic
PROMAZINE ? unclear Mechanistic
STAUROSPORINE ~ modulates Mechanistic
ZAMIFENACIN ? unclear Mechanistic
WIN 51,708 ~ modulates Mechanistic
ALCURONIUM ~ modulates Mechanistic
MEPENZOLATE ↓ inhibits Mechanistic
OLANZAPINE ? unclear Mechanistic
HEXOCYCLIUM ↓ inhibits Mechanistic
HEXAHYDROSILADIFENIDOL ↓ inhibits Mechanistic
IPRATROPIUM CATION ↓ inhibits Mechanistic
ARECOLINE ↑ activates Mechanistic 40.0 nM (Ki)
AE9C90CB ↓ inhibits Mechanistic
WDUO3 ~ modulates Mechanistic
BETHANECHOL ↑ activates Mechanistic
MIVACURIUM ? unclear Mechanistic
PILOCARPINE HYDROCHLORIDE ↑ activates Mechanistic
[3H]N-METHYL SCOPOLAMINE ↓ inhibits Mechanistic
ALEXA-488-TELENZEPINE ↓ inhibits Mechanistic
THIETHYLPERAZINE ? unclear Mechanistic
ARECAIDINE PROPARGYL ESTER ↑ activates Mechanistic
N-CHLOROMETHYL-BRUCINE ~ modulates Mechanistic
P-F-HHSID ↓ inhibits Mechanistic
[3H]QNB ↓ inhibits Mechanistic
TRIDIHEXETHYL ? unclear Mechanistic
NNC 11-1585 ↑ activates Mechanistic
DARIFENACIN ↓ inhibits Mechanistic
PROPANTHELINE BROMIDE ↓ inhibits Mechanistic
PIPERTRAMINE AMIDE ? unclear Mechanistic
PIRENZEPINE ↓ inhibits Mechanistic
TRIFLUPROMAZINE ? unclear Mechanistic
METHOTRIMEPRAZINE ? unclear Mechanistic
ML381 ↓ inhibits Mechanistic
SILAHEXOCYCLIUM ↓ inhibits Mechanistic
BAY2413555 ~ modulates Mechanistic
VINBURNINE ~ modulates Mechanistic

Showing top 40 of 317 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
OCTOTROPINE METHYLBROMIDE ↓ inhibits Mechanistic
TIOTROPIUM ↓ inhibits Mechanistic
BETHANECHOL CHLORIDE ↑ activates Mechanistic
GLYCOPYRRONIUM TOSYLATE ↓ inhibits Mechanistic
REVEFENACIN ↓ inhibits Mechanistic
OXYBUTYNIN ↓ inhibits Mechanistic
MUSCARINIC TOXIN 7 ↓ inhibits Mechanistic
SOLIFENACIN ↓ inhibits Mechanistic
ZAMIFENACIN ? unclear Mechanistic
UMECLIDINIUM BROMIDE ↓ inhibits Mechanistic
ACLIDINIUM ↓ inhibits Mechanistic
PROPIOMAZINE ? unclear Mechanistic
(S)-DIMETINDENE ↓ inhibits Mechanistic
TERODILINE HYDROCHLORIDE ↓ inhibits Mechanistic
IPRATROPIUM CATION ↓ inhibits Mechanistic
PENTYLTHIO-TZTP ↑ activates Mechanistic
CARBAMOYLCHOLINE ↑ activates Mechanistic
IPRATROPIUM BROMIDE ↓ inhibits Mechanistic
DIPHENIDOL ? unclear Mechanistic
METHYLHOMATROPINE ? unclear Mechanistic
PROMAZINE ? unclear Mechanistic
METHSCOPOLAMINE BROMIDE ↓ inhibits Mechanistic
ACETYLCHOLINE CHLORIDE ↑ activates Mechanistic
TROPICAMIDE ↓ inhibits Mechanistic
AZD8683 ↓ inhibits Mechanistic
PIPERTRAMINE ? unclear Mechanistic
TRIDIHEXETHYL ? unclear Mechanistic
MEPENZOLATE BROMIDE ↓ inhibits Mechanistic
TOLTERODINE ↓ inhibits Mechanistic
FESOTERODINE ? unclear Mechanistic
HEXOCYCLIUM METHYLSULFATE ↓ inhibits Mechanistic
SUCCINYLCHOLINE ? unclear Mechanistic
OLANZAPINE ? unclear Mechanistic
SOFPIRONIUM BROMIDE ↓ inhibits Mechanistic
[3H]TIOTROPIUM ↓ inhibits Mechanistic
ML381 ↓ inhibits Mechanistic
PIPERTRAMINE AMIDE ? unclear Mechanistic
MEPENZOLATE ↓ inhibits Mechanistic
ACECLIDINE ↑ activates Mechanistic
OXOTREMORINE ↑ activates Mechanistic 210.0 nM (EC50)

Showing top 40 of 333 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
FILAPIXANT ↓ inhibits Mechanistic
GEFAPIXANT ↓ inhibits Mechanistic
SURAMIN ↓ inhibits Mechanistic 3000.0 nM (EC50)
CAMLIPIXANT ↓ inhibits Mechanistic
RO3 ↓ inhibits Mechanistic
BZATP ↑ activates Mechanistic
ΑΒ-MEATP ↑ activates Mechanistic
AF353 ↓ inhibits Mechanistic
ELIAPIXANT ↓ inhibits Mechanistic
ADENOSINE TRIPHOSPHATE ↑ activates Mechanistic 340.0 nM (EC50)
A317491 ↓ inhibits Mechanistic
AF-906 ↓ inhibits Mechanistic
TNP-ATP ↓ inhibits Mechanistic 0.9 nM (EC50)
SIVOPIXANT ↓ inhibits Mechanistic
SPINORPHIN ~ modulates Mechanistic 0.0481 nM (IC50)
GEFAPIXANT CITRATE ↓ inhibits Mechanistic
CHEMBL335206 ↑ activates Mechanistic 8800.0 nM (EC50)
CHEMBL1628528 ↓ inhibits Mechanistic 2800.0 nM (IC50)
CHEMBL339386 ↑ activates Mechanistic 80.0 nM (EC50)
PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER ↑ activates Mechanistic 9200.0 nM (EC50)
CHEMBL216504 ↓ inhibits Mechanistic 28500.0 nM (IC50)
DIPHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER ↑ activates Mechanistic 740.0 nM (EC50)
ATPGAMMAS ↑ activates Mechanistic 690.0 nM (EC50)
CHEMBL129841 ↑ activates Mechanistic 13000.0 nM (EC50)
ISOPPADS ↓ inhibits Mechanistic 84.0 nM (IC50)
CHEMBL74121 ↓ inhibits Mechanistic 58300.0 nM (IC50)
CHEMBL133930 ↓ inhibits Mechanistic 1000.0 nM (IC50)
CHEMBL130094 ↑ activates Mechanistic 350.0 nM (EC50)
CHEMBL337062 ↑ activates Mechanistic 17.0 nM (EC50)
CHEMBL336208 ↑ activates Mechanistic 350.0 nM (EC50)
CHEMBL69234 ↑ activates Mechanistic 240.0 nM (EC50)
DIADENOSINE TETRAPHOSPHATE ↑ activates Mechanistic 500.0 nM (EC50)
CHEMBL413145 ↓ inhibits Mechanistic 354.81 nM (IC50)
CHEMBL397926 ↓ inhibits Mechanistic 82.4 nM (IC50)
CHEMBL395723 ↓ inhibits Mechanistic 32.4 nM (IC50)
CHEMBL238310 ↓ inhibits Mechanistic 14.3 nM (IC50)
CHEMBL599760 ↓ inhibits Mechanistic 398.11 nM (IC50)
CHEMBL2010928 ↓ inhibits Mechanistic 1360.0 nM (IC50)
CHEMBL2010929 ↓ inhibits Mechanistic 618.0 nM (IC50)
CHEMBL2010930 ↓ inhibits Mechanistic 327.0 nM (IC50)

Showing top 40 of 202 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
INCOBOTULINUMTOXINA ↓ inhibits Mechanistic
PRABOTULINUMTOXIN A ? unclear Mechanistic
THERAPEUTIC STEROID HORMONE ? unclear Mechanistic
AMISULPRIDE ? unclear Mechanistic
DAXIBOTULINUMTOXINA ↓ inhibits Mechanistic
TRENIBOTULINUMTOXINE ? unclear Mechanistic
LETIBOTULINUMTOXINA ? unclear Mechanistic
ONABOTULINUMTOXINA ↓ inhibits Mechanistic
BOTULINUM TOXIN TYPE A ? unclear Mechanistic
DIAZOXIDE ? unclear Mechanistic
ABOBOTULINUMTOXINA ? unclear Clinical
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ASP7663 ↑ activates Mechanistic
NPPB ↑ activates Mechanistic
VOACANGINE ? unclear Mechanistic
METHYLGLYOXAL ↑ activates Mechanistic
ALLYL ISOTHIOCYANATE ↑ activates Mechanistic 33500.0 nM (EC50)
BENZYL BROMIDE ↑ activates Mechanistic 12000.0 nM (EC50)
1,6-HEXAMETHYLENE DIISOCYANATE ↑ activates Mechanistic
BROMOACETONE ↑ activates Mechanistic
ACETALDEHYDE ↑ activates Mechanistic
ISOVELLERAL ↑ activates Mechanistic 590.0 nM (EC50)
POLYGODIAL ↑ activates Mechanistic 59.0 nM (EC50)
CISPLATIN ? unclear Mechanistic
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic
A-967079 ↓ inhibits Mechanistic
NITROOLEIC ACID ↑ activates Mechanistic
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic 10000.0 nM (EC50)
PF-4840154 ↑ activates Mechanistic
4-HYDROXYNONENAL ? unclear Mechanistic
AM-0902 ↓ inhibits Mechanistic
ACROLEIN ↑ activates Mechanistic 5000.0 nM (EC50)
1'-ACETOXYCHAVICOL ACETATE ↑ activates Mechanistic
GDC-0334 ↓ inhibits Mechanistic
METHYL ISOCYANATE ↑ activates Mechanistic
BUTAMBEN ↓ inhibits Mechanistic
ERUCIN ? unclear Mechanistic
CHLOROPICRIN ↑ activates Mechanistic
SALIRASIB ↑ activates Mechanistic 5000.0 nM (EC50)
BUTAMBEN PICRATE ↓ inhibits Mechanistic
MENTHOL ↑ activates Mechanistic 28400.0 nM (EC50)
CHLOROBENZYLIDENE MALONONITRILE ↑ activates Mechanistic
HC030031 ↓ inhibits Mechanistic
URB597 ↑ activates Mechanistic
JT010 ↑ activates Mechanistic
DIBUTYLPHTHALATE ↑ activates Mechanistic
AP18 ↓ inhibits Mechanistic
TCS 5861528 ↓ inhibits Mechanistic
APOMORPHINE ↑ activates Mechanistic
CB-189625 ↓ inhibits Mechanistic
BENZOQUINONE ↑ activates Mechanistic
GRC-17536 ↓ inhibits Mechanistic

Showing top 40 of 186 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
RHTX ↑ activates Mechanistic
ABT-102 ↓ inhibits Mechanistic
ASIVATREP ↓ inhibits Mechanistic
BCTC ↓ inhibits Mechanistic
MAVATREP ↓ inhibits Mechanistic
POLYGODIAL ? unclear Mechanistic
ALLICIN ↓ inhibits Mechanistic
JTS-653 ↓ inhibits Mechanistic
SB452533 ↓ inhibits Mechanistic
MR-1817 ↓ inhibits Mechanistic
GRC-6211 ↓ inhibits Mechanistic
ACETAMINOPHEN ↑ activates Mechanistic
DWP05195 ↓ inhibits Mechanistic
STREPTOZOCIN ? unclear Mechanistic
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50)
AMG517 ↓ inhibits Mechanistic
5S-HETE ↑ activates Mechanistic
BENZYL ISOTHIOCYANATE ? unclear Mechanistic
MASOPROCOL ? unclear Mechanistic
[3H]RESINIFERATOXIN ↑ activates Mechanistic
[3H]A778317 ↓ inhibits Mechanistic
CAPSAZEPINE ↓ inhibits Mechanistic 120.0 nM (Ki)
NABIXIMOLS ? unclear Mechanistic
H+ ↑ activates Mechanistic
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
NADA ↓ inhibits Mechanistic
ZUCAPSAICIN ↑ activates Mechanistic
SB366791 ↓ inhibits Mechanistic
GRC-15300 ? unclear Mechanistic
MRS-1477 ~ modulates Mechanistic
ANANDAMIDE ↑ activates Mechanistic
JNJ17203212 ↓ inhibits Mechanistic
LEVODOPA ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
AZD1386 ↓ inhibits Mechanistic
CAMPHOR OIL ↑ activates Mechanistic
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic
VOACANGINE ? unclear Mechanistic
FERRUGINENE B ? unclear Mechanistic
PHENYLACETYLRINVANIL ↑ activates Mechanistic

Showing top 40 of 187 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Overactive Bladder (OAB): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT06953271 Phase: 4 Started: 2025-08-01

The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis med...

NCT07195656 Phase: N/A Started: 2025-09-30

A study to evaluate the safety and effectiveness of FemPulse System

NCT07405554 Phase: 2 Started: 2026-02-26

This randomized, double-blind, placebo-controlled trial evaluates whether oral zinc plus phytase supplementation modifies clinical response to intradetrusor botulinum toxin injection in patients with overactive bladder. Participants will receive either zinc plus phytase supplementation or matching p...

NCT05557279 Phase: 2 Started: 2023-01-01

The purpose of this study is to learn about how the use of 500 mg of dried cranberry powder extract (NDS-446) changes the bacteria that normal reside in the bladder of women who don't have urinary leakage problems but do have problems with urinary urgency and frequency.

NCT07473310 Phase: 4 Started: 2025-11-11

The goal of this clinical trial is to evaluate the effectiveness and safety of low-intensity shockwave therapy (Li-SWT) for the treatment of overactive bladder (OAB) in adult women. The main questions this study aims to answer are whether Li-SWT improves overactive bladder symptoms and quality of li...

NCT05308979 Phase: 4 Started: 2022-05-01

Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.

NCT07416968 Phase: 4 Started: 2025-09-01

Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage. Women who join the study will be randomly placed into one of two groups: One group will take tadalafil (5 mg),...

NCT06780163 Phase: 4 Started: 2025-06-27

The goal of this Pre-Post Quasi-experimental study is to investigates the effect of vaginal estrogen therapy on changes in the urinary microbiome and its association with improvement in overactive bladder (OAB) symptoms in menopausal women Primary Objective: To evaluate the effects of vaginal estrog...

NCT06489951 Phase: N/A Started: 2024-12-28

The aim of this study is to give children with dry OAB: (1) Standard behavioral therapy combined with classical anticholinergic drugs (Solinaxine), or (2) standard behavioral therapy combined with short-term high-dose exogenous vitamin D supplementation are used to compare the outcomes of lower urin...

NCT07081906 Phase: N/A Started: 2019-02-15

This is a prospective, randomized controlled clinical trial designed to compare the efficacy and safety of transdermal versus oral oxybutynin in children diagnosed with overactive bladder (OAB) who remain symptomatic despite conservative management. A total of 90 children were planned to be enrolled...

NCT07025642 Phase: N/A Started: 2025-07-01

Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A...

NCT02656173 Phase: 4 Started: 2016-01-25

The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.

NCT04103450 Phase: 3 Started: 2019-09-19

This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).

NCT03902080 Phase: 3 Started: 2019-03-26

This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.

NCT04124939 Phase: 4 Started: 2019-11-10

The purpose of this research study is to help determine if 10 injections of Botox ® 100 units is less painful than 20 injections of Botox ® 100 units based on effectiveness in reducing urge incontinence episodes. Study will also be assessed for the pain of procedure and adverse outcomes of 20 inject...


Agents Found By Disease-Level Search

Searched directly from “Overactive Bladder (OAB)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

39 agents shown (approved or with trial evidence) — 30 not found by the gene-target search above.

fesoterodine

Approved · 8 trials · source: ClinicalTrials.gov, Open Targets
NCT01286454 NCT01286454 NCT01286454

Mirabegron

Approved · 6 trials · source: ClinicalTrials.gov, Open Targets
NCT00662909 NCT00689104 NCT02092181

Tolterodine

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00689104 NCT00876421 NCT00703703

botulinum toxin Type A

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00915525 NCT02161159 NCT02601287

ONO-8539NOT in gene-target list

Phase 2 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00876421 NCT00876421 NCT00876421

solifenacin

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01745094 NCT02667470

Oxybutynin

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00224016 NCT00224016

mirabegron (YM178)NOT in gene-target list

Approved · 2 trials · source: ClinicalTrials.gov
NCT00840645 NCT00337090

Pumpkin Seed ExtractNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06944392

onabotulinumtoxinA

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02557971

Fesoterodine fumarate

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00798434

oxybutynin chloride

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00293839

Bladder diaryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03807024

tarafenacin (SVT-40776)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00507169

500 mg NDS-446NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05557279

Medication GroupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07195656

Sativex®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00678795

Solifenacin Succinate 5mg/tab dailyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04477265

Solifenacin Succinate TabletsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01833663

EstrogenNOT in gene-target list

Unknown · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01833663

Strain ElastographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06933407

Liposome encapsulated botulinum toxin ANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01167257

PTNSNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02657057

Diary pod ( measuring vessel that automatically calculates voided volume)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05702294

Conventional fluoroscopyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04527445

visceral fat obesity (surface area and function)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03750604

Solabegron immediate release tablets, low doseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03475706

Solabegron immediate release tablets, high doseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03475706

JLP-2002NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04914221

ComparatorNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04914221

Injection of Onabotulinum toxinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03388086

fesoterodine (SPM 907)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT00138723

ritobegron (KUC-7483)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00742833

Tolterodine tartrate extended release capsulesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01729819

Desmopressin orally disintegrating tabletsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01729819

Paced RespirationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02202031

Music TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02202031

Lidocaine patchNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05783219

JLP-2002 A mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04917315

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.